What Makes Maze Therapeutics, Inc. (MAZE) a New Buy StockZacks Investment Research · 6 days ago
How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%Zacks Investment Research · Oct 19, 2026
Here Are Monday’s Top Wall Street Analyst Research Calls: Ameriprise Financial, Boyd Gaming, CoreWeave, Datadog, Intel, JetBlue Airways, PayPal Holdings, Pinterest, Whirlpool, and More247 Wallst · Oct 19, 2026
Maze Therapeutics (NASDAQ:MAZE) vs. Nektar Therapeutics (NASDAQ:NKTR) Financial AnalysisDefense World · Oct 16, 2026
Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK)Defense World · Oct 13, 2026
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026GlobeNewsWire · Oct 6, 2026Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.72 | -$0.76 | Miss |
| May 12, 2026 | -$0.43 | -$0.45 | Miss |
| Mar 25, 2026 | -$0.73 | -$0.65 | Beat |
| Nov 6, 2025 | -$0.74 | -$0.66 | Beat |
| Aug 12, 2025 | -$0.79 | -$0.77 | Beat |
| May 14, 2025 | -$0.76 | -$1.15 | Miss |